Now North Carolina newcomer OXB, a UK-based CDMO in cell and gene therapy, announced Oct.7 that it has acquired the former ...

QHP Capital ("QHP") today announced an investment in Vector Clinical Trials ("Vector" or the "Company"), a leading clinical research site network led by Founder Dr. Bobby Mocherla.

OXB, formerly known as Oxford BioMedica, is expanding in a heartland of the US life science marketplace through the purchase ...

OXB has signed and closed an asset purchase transaction to acquire a custom-built cell and gene therapy viral vector manufacturing facility in ...

OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s ...

Following the acquisition, Oxford BioMedica's existing Bedford, Massachusetts site will remain "an AAV centre of excellence for process and analytical development", focusing on early-stage development ...